Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CYSLTR1 Biologics Sequence Review Report 2026: Cysteinyl leukotriene receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CYSLTR1 Biologics Sequence Review Report 2026: Cysteinyl leukotriene receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CYSLTR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXADR Biologics Sequence Review Report 2026: Coxsackievirus and adenovirus receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXADR Biologics Sequence Review Report 2026: Coxsackievirus and adenovirus receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CXADR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CTAG2 Biologics Sequence Review Report 2026: Cancer/testis antigen 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CTAG2 Biologics Sequence Review Report 2026: Cancer/testis antigen 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CTAG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CTAG1A Biologics Sequence Review Report 2026: Cancer/testis antigen 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CTAG1A Biologics Sequence Review Report 2026: Cancer/testis antigen 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CTAG1A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CT55 Biologics Sequence Review Report 2026: Cancer/testis antigen 55 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CT55 Biologics Sequence Review Report 2026: Cancer/testis antigen 55 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CT55 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CT45A1 Biologics Sequence Review Report 2026: Cancer/testis antigen family 45 member A1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CT45A1 Biologics Sequence Review Report 2026: Cancer/testis antigen family 45 member A1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CT45A1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CRHR2 Biologics Sequence Review Report 2026: Corticotropin-releasing hormone receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CRHR2 Biologics Sequence Review Report 2026: Corticotropin-releasing hormone receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CRHR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CR1 Biologics Sequence Review Report 2026: Complement receptor type 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CR1 Biologics Sequence Review Report 2026: Complement receptor type 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CMKLR1 Biologics Sequence Review Report 2026: Chemerin-like receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CMKLR1 Biologics Sequence Review Report 2026: Chemerin-like receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CMKLR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLNK Biologics Sequence Review Report 2026: Cytokine-dependent hematopoietic cell linker Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLNK Biologics Sequence Review Report 2026: Cytokine-dependent hematopoietic cell linker Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CLNK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLCF1 Biologics Sequence Review Report 2026: Cardiotrophin-like cytokine factor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLCF1 Biologics Sequence Review Report 2026: Cardiotrophin-like cytokine factor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CLCF1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CKLF Biologics Sequence Review Report 2026: Chemokine-like factor Similarity and Patent-Risk Signals
8 min read
CKLF Biologics Sequence Review Report 2026: Chemokine-like factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CKLF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →